

POSTER Session I, Tuesday, June 7, 2022, 10:10 am - 10:55 am Leaders: Ingrid Lundberg, Kanneboyina Nagaraju

Presenting author

- P-7** Spatial transcriptomic analysis of dermatomyositis muscle unveils a unique signature in atrophic perifascicular muscle fibers. Andrew L Mammen
- P-8** A SQSTM1 polymorphism confers risk for Sporadic Inclusion Body Myositis disease expression. Marrilee Nedham
- P-20** Description of macrophages in idiopathic inflammatory myopathies using in-situ RNAseq. Julian Dal Cin
- P-35** Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy (IMNM). Sarah Julien
- P-43** Evaluation of major histocompatibility complex class II in idiopathic inflammatory myopathies. Laure Gallay
- P-46** Identification of anti-flagellin antibodies in juvenile dermatomyositis using an antibody profiling technology. Sahan Jayaraman

POSTER Session II, Tuesday, June 7, 2022, 2:50 pm - 3:35 pm Leaders: Victoria Werth, Albert Selva O' Callagan

- P-57** COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy individuals: results from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Latika Gupta
- P-70** Power Doppler ultrasonography for the monitoring of patients affected by idiopathic inflammatory myopathies. Edoardo Conticini
- P-75** Immunogenetics features of Dermatomyositis-Associated Malignancies. Albert Selva-O'Callaghan
- P-77** Diagnosis accuracy of muscle MRI for autoimmune myopathies: Multicentric prospective study (DARWIM). Yves Allenbach
- P-79** Achieving clinical remission in anti-HMGCR positive immune-mediated necrotizing myopathy with a corticosteroid-free treatment: report from a single center. Maryam Dastmalchi
- P-80** 18-FDG PET-CT diagnostic value in immune checkpoint inhibitor induced Myositis. Yves Allenbach
- P-82** Improvement in Disease Activity in Refractory Juvenile Dermatomyositis following Abatacept Therapy: Results of the Abatacept in Dermatomyositis (AID) Trial. Rodolfo Victor Curiel

POSTER Session III, Wednesday, June 8, 2022, 10:45 am - 11:30 am Leaders: Lisa Rider, Mazen Dimachkie

- P-97** Using Smartphone-Based App Collected Daily Symptom Data to Identify and Investigate Characteristics of Myositis Flares - Towards Real-Time Flare Detection and Personalised Management. Alexander Oldroyd
- P-107** Successful Management with Tofacitinib in Adult and Juvenile Dermatomyositis. Hailey Bowler
- P-115** Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin for idiopathic inflammatory myositis: a multicenter observational study. Maria Giovanna Danieli
- P-123** Comparing histopathology, transcriptomic and proteomic profiles of sporadic inclusion body myositis (sIBM) and polymyositis with mitochondrial pathology (PM-Mito): are we moving towards sIBM-spectrum disease (IBM-SD)? Felix Kleefeld
- P-127** IL-1 β and IFN γ combined increase sarcoplasmic p62 puncta size but do not influence TDP-43 aggregation in healthy myotubes. Bryony McCord
- P-133** Phenotypical and Clinical Indications of a Lymphoproliferative Disorder of CD8+ T cell Large Granular Lymphocytes Among Inclusion Body Myositis Patients. Jerome Coudert
- P-138** Cell type-specific transcriptomic trajectories underlying disease progression in inclusion body Myositis. Sven Wischniewski

POSTER Session IV, Wednesday, June 8, 2022, 3:15 pm - 4:00 pm Leaders: Marianne de Visser, Hector Chinoy

- P-146** High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey. Latika Gupta
- P-153** Validation of the 2016 ACR/EULAR Myositis Improvement Criteria in Adult Dermatomyositis and Polymyositis Clinical Trials and Consensus Profiles. Didem Saygin
- P-168** Patients with idiopathic inflammatory myopathies who report low levels of physical activity report higher levels of anxiety and depression - a cross-sectional study of self-reported data. Kristofer Andreasson
- P-169** The Pattern of Major Histocompatibility Complex Class I Expression in Muscle Biopsies from Patients with Different Types of Myositis and other Neuromuscular Disorders. Andrew L Mammen
- P-178** Clinical characteristic defining antisynthetase syndrome: results from the univariate analysis on the class project's dataset. Giovanni Zanframundo
- P-181** IFN-I dependent impairment of muscle stem cell proliferation in dermatomyositis. Laure GALLAY
- P-182** Further delineation of the idiopathic eosinophilic myositis, a clinical-pathological analysis of a cases series. Laure GALLAY